

EXHIBIT 3

Equity Holders

JOINT APPENDIX 3

This Joint Appendix identifies the Existing Equity Holders referenced in the Agreement and entitled under the Agreement to parity treatment corresponding to the Holder's interest. This Appendix may be amended to add additional interest-holders. It may not otherwise be altered, amended, modified, or superseded in a way that would dilute the interest of any interest holder without the express written

Name	Agreement Type	Agreement Date	Consideration Received	% Interest
Funder I	Investment	May 2, 2016	\$250,000	0.1250%
Funder I	Investment	July 11, 2016	\$100,000	0.0500%
Funder II	Investment	July 11, 2016	\$250,000	0.1375%
Funder III	Investment	August 24, 2016	\$200,000	0.1100%
Funder IV	Investment	August 24, 2016	\$300,000	0.1815%
Funder IV	Investment	November 1, 2016	\$100,000	0.0605%
Funder V	Investment	November 14, 2016	\$250,000	0.1375%
Funder VI	Investment	February 3, 2017	\$152,000	0.0760%
Funder VII	Investment	*Dec 2017*	\$250,000	0.2500%
Lawyer - SRD	Services	November 1, 2017		6.3000%
Lawyer – AMP	Services	January 11, 2017		0.2500%
Lawyer - PS	Services	September 28, 2016		0.2500%
Lawyer - AS	Services	September 28, 2016		0.2500%
Lawyer - PG	Services			0.0000%
Lawyer - JP	Services			0.0000%
Lawyer - EG	Services			0.1250%
Services – KH	Services	January 11, 2017		0.1250%
Consulting - BB	Services			0.6000%
Consulting - DM	Services			0.2000%
Consulting - TRG	Services			0.2500%
Consulting - PF	Services			0.2500%
Consulting - KS	Services			0.1250%
TOTAL			<u>\$1,852,000</u>	<u>9.8530%</u>

***Special Disclosure**

The table in Appendix 3 does not reflect all potential claims that may be brought against the FDA in the event of a recovery of judgment proceeds. Any purported prior existing interests not reflected in the chart will be considered after the presentation of a claim by the purported interest-holder. Claimants might include, for example, law firms that worked on the matter on a contingency basis in prior years that then abandoned the litigation under pressure from Chevron or for any business reason. The FDA generally maintains the position that any interests once held by particular claimants who abandoned the litigation, or who signed agreements with Chevron, have been forfeited in their entirety. If necessary, and independent of the interests reflected in the table, funds might be set aside from the judgment proceeds to handle potential claims from prior existing interests. Some of the potential claims of prior existing interests might be negotiated to resolution to avoid litigation. The FDA expects that the handling of all such actions related to prior existing interests will occur after the interests on the chart have been paid subsequent to any recovery.

Krevlin
Krevlin
Eisler

JVM
JVM
IW
RW
TA

Forfeited/Disputed

Name	Agreement Type	Agreement Date	Fixed	%	Disputed	Forfeited
Treca						1.47%
Torvia						7.48%
DeLeon						1.40%
Woodsford						0.66%
Temeaire						0.50%
Patton Boggs						5.00%
Nextant						0.30%
H5						1.25%
Motley Rice					3.30%	
ECBA					2.00%	
Maples					2.00%	
Kohn, Swift & Graf					0.00%	
Oren Kramer					0.06%	
Fromboliere					2.00%	
SKV (Smyser)					1.00%	
TOTAL					10.36%	18.06%

Shares attached to SRD interest

Rich Friedman				0.32%	
Zoe Littlepage				0.32%	
Glen Krevlin	Loan Conversion‡	February 7, 2011	\$ 250,000		
David Sherman	Loan Conversion‡	February 17, 2011	\$ 125,000		
TOTAL				0.63%	